Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Details werden geladen...

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/design-therapeutics-to-host-investor-webcast-to-review-data-from-restore-fa-trial-of-dt-216p2-for-friedreichs-ataxia-on-monday-may-18-2026/2345763

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 | The Manila Times

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia | The Manila Time...

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/design-therapeutics-announces-four-week-iv-data-from-the-restore-fa-trial-of-dt-216p2-demonstrating-clinical-improvements-and-comprehensive-biomarker-activity-in-friedreich-ataxia/2346077

AVITA Medical to Host Investor Webinar Briefing | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/avita-medical-to-host-investor-webinar-briefing/2345776

EyePoint Announces Participation at Upcoming Investor Conferences | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/eyepoint-announces-participation-at-upcoming-investor-conferences/2346999

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/lexeo-therapeutics-to-participate-in-the-2026-rbc-capital-markets-global-healthcare-conference/2347013

$https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652$

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/cullinan-therapeutics-to-present-initial-clinical-data-for-cln-978-in-treatment-refractory-rheumatoid-arthritis-and-systemic-lupus-erythematosus-at-eular-2026-congress/2346652

SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting | The Manila Times

https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/seed-therapeutics-to-present-phase-1-trial-design-for-st-01156-a-first-in-human-oral-rbm39-molecular-glue-degrader-at-2026-asco-annual-meeting/2346087

Login